U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2008
174
Substance Class Protein
Created
by admin
on Mon Mar 31 18:30:02 GMT 2025
Edited
by admin
on Mon Mar 31 18:30:02 GMT 2025
Protein Sub Type
Sequence Type COMPLETE
Record UNII
6KIC4BB60G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HUMAN C1-ESTERASE INHIBITOR
Common Name English
C1 INHIBITOR (HUMAN)
EMA EPAR   VANDF  
Preferred Name English
CINRYZE
Brand Name English
PLASMA PROTEASE C1 INHIBITOR
Common Name English
C1 INHIBITOR (HUMAN) [VANDF]
Common Name English
C1-ESTERASE-INHIBITOR, HUMAN, PASTEURIZED
Common Name English
C1-ESTERASE INHIBITOR (RECOMBINANT)
Common Name English
COMPLEMENT C1 ESTERASE INHIBITOR [MART.]
Common Name English
C1 INHIBITOR (HUMAN) [EMA EPAR]
Common Name English
C1 ESTERASE INHIBITOR (HUMAN)
Common Name English
RVG-19303
Code English
BERINERT
Brand Name English
C1-INHIBITOR, PLASMA DERIVED
WHO-DD  
Common Name English
C1 ESTERASE INHIBITOR, HUMAN
Common Name English
C1-ESTERASE INHIBITOR, HUMAN
Common Name English
HUMAN C1-ESTERASE INHIBITOR [EP MONOGRAPH]
Common Name English
CETOR
Brand Name English
C1 INHIBITOR [VANDF]
Common Name English
C1-inhibitor, plasma derived [WHO-DD]
Common Name English
C1-INHIBITING FACTOR
Common Name English
C1 INHIBITOR
VANDF  
Common Name English
C1 INHIBITOR HUMAN
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 123599
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 510415
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 46590
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 46590
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
EMA ASSESSMENT REPORTS CINRYZE (AUTHORIZED: ANGIOEDEMAS, HEREDITARY)
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 67592
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 602117
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
WHO-ATC B06AC01
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 510415
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 95296
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
NCI_THESAURUS C471
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 46490
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
NDF-RT N0000184172
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
NDF-RT N0000184172
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 185804
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 46490
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
FDA ORPHAN DRUG 95296
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
EU-Orphan Drug EU/3/09/668
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
Code System Code Type Description
RXCUI
809864
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY RxNorm
NDF-RT
N0000010252
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY Decreased Vascular Permeability [PE]
EVMPD
SUB130159
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
NCI_THESAURUS
C87730
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
EVMPD
SUB39564
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
SMS_ID
100000129592
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
DRUG BANK
DB06404
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
EVMPD
SUB39564
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
DAILYMED
6KIC4BB60G
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
CAS
1018837-94-9
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
FDA UNII
6KIC4BB60G
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY
NDF-RT
N0000184151
Created by admin on Mon Mar 31 18:30:02 GMT 2025 , Edited by admin on Mon Mar 31 18:30:02 GMT 2025
PRIMARY Kallikrein Inhibitors [MoA]
From To
1_101 1_406
1_108 1_183
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_3
N 1_47
N 1_59
N 1_216
N 1_231
N 1_250
N 1_330
O 1_26
O 1_49
O 1_61
O 1_66
O 1_70
O 1_74
Related Record Type Details
HUMAN C1-ESTERASE INHIBITOR
ACTIVE MOIETY
HUMAN C1-ESTERASE INHIBITOR
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966